







Capital Markets Day

Epidemiology

December 10, 2019




Agenda


Immunology	
Vaccines	
Rare Diseases	
Multiple Sclerosis / Neurology	
Rare Blood Disorders	
Oncology	

Dupixent®: Atopic Dermatitis Adult 18+


2018 number of patients (thousands)




Dupixent®: Atopic Dermatitis Adolescents 12-17yo



Dupixent®: Atopic Dermatitis Child 6-11yo




Dupixent[®]: Atopic Dermatitis Child <6yo



Dupixent[®]: Asthma 12+

2018 number of patients (thousands)



Source: Sanofi analysis

ICS: Inhaled Corticosteroids; OCS: Oral Corticosteroids


(1) Germany, France, Italy, Spain & United Kingdom

(2) For EU, severe with persistent use of ICS or OCS

(3) For EU, severe uncontrolled or OCS dependent

Dupixent®: Asthma 6-11yo

2018 number of patients (thousands)



Source: Sanofi analysis


ICS: Inhaled Corticosteroids; OCS: Oral Corticosteroids

(1) Germany, France, Italy, Spain & United Kingdom

(2) For EU, severe with persistent use of ICS or OCS


(3) For EU, severe uncontrolled or OCS dependent

Dupixent[®]: Eosinophilic Esophagitis 12+



Dupixent[®]: Chronic Rhinosinusitis with Nasal Polyposis


2018 number of patients (thousands)




Inadequately controlled CRSwNP⁽²⁾

Patients uncontrolled despite prior surgery


Dupixent[®]: Bullous Pemphigoid 18+




Dupixent[®]: Prurigo Nodularis 12+



Dupixent®: Chronic Spontaneous Urticaria



Dupixent®: Chronic Obstructive Pulmonary Disease









Source: Sanofi analysis


SoC: Standard of Care; GOLD criteria: Global Initiative for Chronic Obstructive Lung Disease - Group D: high risk (≥ 2 exacerbations / year, or one+ requiring hospitalization) and more symptoms (mMRC ≥ 2 or CAT ≥ 10)

(1) Germany, France, Italy, Spain & United Kingdom







Agenda

Immunology	
Vaccines	
Rare Diseases	
Multiple Sclerosis / Neurology	
Rare Blood Disorders	
Oncology	

Nirsevimab: RSV




Agenda


Immunology	
Vaccines	
Rare Diseases	
Multiple Sclerosis / Neurology	
Rare Blood Disorders	
Oncology	

Venglustat: Gaucher Disease Type 3


Breakdown of diagnosed GD patients⁽²⁾



Venglustat: GM2 gangliosidoses




Venglustat: Fabry Disease




~60% of diagnosed patients are treated today

Venglustat: ADPKD

2018 number of patients (thousands)




Avalglucosidase alfa: Pompe Disease




Today, ~20% of treated Pompe Disease patients are IOPD

Olipudase alfa: Acid Sphingomyelinase Deficiency









miRNA21: Alport Syndrome


2018 estimated number of patients⁽²⁾




Agenda

Immunology	
Vaccines	
Rare Diseases	
Multiple Sclerosis / Neurology	
Rare Blood Disorders	
Oncology	


MS: Primary Progressive Multiple Sclerosis



MS: Non-Relapsing Secondary Progressive MS




MS: Relapsing Forms of Multiple Sclerosis









Venglustat: GBA-PD

2018 number of patients (thousands)




Early PD defined as Hoehn and Yahr (H&Y) stage of <3

Agenda

Immunology	
Vaccines	
Rare Diseases	
Multiple Sclerosis / Neurology	
Rare Blood Disorders	
Oncology	


Fitusiran & BIVV001: Hemophilia A

2018 number of patients (thousands)




Fitusiran: Hemophilia B


2018 number of patients (thousands)









Sutimlimab: Cold Agglutinin Disease



Sutimlimab: Immune Thrombocytopenia




Agenda

Immunology	
Vaccines	
Rare Diseases	
Multiple Sclerosis / Neurology	
Rare Blood Disorders	
Oncology	


SERD: HR+/HER2- Breast Cancer

2018 number of eligible treated patients⁽²⁾ (thousands)




Sarclisa[®]: Multiple Myeloma

2018 number of treated patients (thousands)




Libtayo[®]: Cutaneous Squamous Cell Carcinoma

2018 number of patients (thousands)




Libtayo®: Non-Small-Cell Lung Carcinoma




Anti-CEACAM5: Non-Small-Cell Lung Carcinoma

2018 number of patients (thousands)




Libtayo®: Basal Cell Carcinoma

2018 number of patients (thousands)



Libtayo®: Cervical Cancer






Illustration of an Interleukin 4 (pink) binding to its receptor (dark and light blue). Getty Images – Juan Gaertner

Capital Markets Day

Epidemiology

December 10, 2019



For further information please contact:

Investor Relations

Paris Tel: +33 1 53 77 45 45

Bridgewater Tel: +1 908 981 5560

Email: IR@sanofi.com

Media Relations

Tel: +33 1 53 77 46 46

Email: MR@sanofi.com

www.sanofi.com

54, rue de la Boétie – 75008 Paris - FRANCE

